enGene Therapeutics Inc. ENGN
1.80 USD +0.13 (+7.78%)
At closeNov 11, 2026, 7:59 PM EST
1.82 +0.02 +1.11%
After hours · Nov 11, 7:59 PM ET
1.63 Day range 1.81
1.40 52-week range 12.25
- YTD
- -80.07%
- 1 year
- -79.59%
News
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript enGene Therapeutics Inc. (ENGN) Discusses Updated LEGEND Data and Regulatory Path for Detalimogene Transcript
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
businesswire.com enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated results from the…
businesswire.com enGene Appoints Key Executives in Anticipation of Upcoming Regulatory and Commercial Milestones BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointments of…
businesswire.com enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
defenseworld.net enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages enGene Holdings Inc. (NASDAQ: ENGN - Get Free Report) has earned an average recommendation of "Hold" from the fourteen research firms that are presently covering the stock, MarketBeat Ratings…
marketbeat.com enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse,…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript
businesswire.com enGene to Host KOL Webinar on October 15, 2026 BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk…
benzinga.com Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.- benzinga.com enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of…
businesswire.com enGene Reports Third Quarter 2026 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results…
businesswire.com enGene to Participate in Upcoming Investor Conferences BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will…
defenseworld.net Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN) enGene (NASDAQ: ENGN - Get Free Report) and Oncobiologics (NASDAQ: OTLK - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies…
marketbeat.com enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a…
seekingalpha.com enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript
businesswire.com enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a…
benzinga.com EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
businesswire.com enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of…
globenewswire.com Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to…
benzinga.com This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday Wall Street analysts updated ratings for CURB, INTU, ENGN. See their outlooks and targets at Benzinga's analyst ratings page.
benzinga.com Morgan Stanley Downgrades enGene Therapeutics to Underweight Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.
benzinga.com W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday Top analysts changed ratings on top names, including Sunrun, enGene Therapeutics, Camp4 Therapeutics, PennyMac Financial, Dave & Buster's, Neumora Therapeutics, Extra Space Storage, & W. P. Carey.…
benzinga.com HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $6 to $4.- benzinga.com EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202 Recent Corporate UpdatesReduction in Force and Executive Departures: In June 2026, enGene implemented a plan to reduce its workforce by approximately 50% to streamline operations and preserve cash.…
- benzinga.com enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.47) by 8.51 percent. This is a 15.69 percent increase over losses of…
businesswire.com enGene Reports Second Quarter 2026 Financial Results and Provides Business Update BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial results for…
prnewswire.com ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics…
prnewswire.com ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm LOS ANGELES, June 8, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of enGene Therapeutics…
benzinga.com Why Is enGene Therapeutics Stock Falling Friday? enGene stock sinks after Phase 2 bladder cancer trial shows durability concerns. Analysts slash price forecasts as the sell-off intensifies.- benzinga.com Citizens Downgrades enGene Therapeutics to Market Perform Citizens analyst Silvan Turkcan downgrades enGene Therapeutics (NASDAQ:ENGN) from Market Outperform to Market Perform.
- benzinga.com Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2 Wells Fargo analyst Yanan Zhu downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Equal-Weight and lowers the price target from $25 to $2.
- benzinga.com HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6 HC Wainwright & Co. analyst Andres Y. Maldonado maintains enGene Therapeutics (NASDAQ:ENGN) with a Buy and lowers the price target from $25 to $6.
- benzinga.com Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4 Piper Sandler analyst Allison Bratzel downgrades enGene Therapeutics (NASDAQ:ENGN) from Overweight to Neutral and lowers the price target from $7 to $4.
benzinga.com Dow Dips 350 Points; US Foods Posts Downbeat Earnings Dow falls over 100 points, S&P 500 and NASDAQ also down. Tech sector up, energy stocks down. US Foods reports lower Q1 earnings and sales. Agilon Health, Aaon, and Rackspace Technology see gains…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com US Stocks Mixed; Dow Falls Over 100 Points US stocks higher Thursday morning, Dow down 0.28%, Nasdaq up 0.50%, S&P 500 up 0.07%. Tech sector up 1.1%, energy sector down 2.8%. McDonald's reports strong earnings and sales.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session - benzinga.com WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5 WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.
- benzinga.com enGene Holdings To Change Its Corporate Name To enGene Therapeutics Effective April 8 Name change reflects transition towards potential commercial organization in 2027Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026enGene Therapeutics Inc. (formerly,…
- benzinga.com Oppenheimer Maintains Outperform on enGene Holdings, Lowers Price Target to $30 Oppenheimer analyst Leland Gershell maintains enGene Holdings (NASDAQ:ENGN) with a Outperform and lowers the price target from $33 to $30.
benzinga.com HC Wainwright & Co. Reiterates Buy on enGene Holdings, Maintains $25 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates enGene Holdings (NASDAQ:ENGN) with a Buy and maintains $25 price target.- benzinga.com enGene Holdings Q1 EPS $(0.44) Beats $(0.58) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.58) by 24.53 percent. This is a 8.33 percent increase over losses of…
- benzinga.com enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.3 percent. This is a 114.71 percent decrease over losses of…
benzinga.com enGene Holdings Says FDA Selects Detalimogene Voraplasmid To Participate In Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program enGene one of nine companies awarded CDRP per yearProgram aims to support CMC development of products with expedited clinical development timeframes and provide patients with earlier access to these…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Morgan Stanley Maintains Overweight on enGene Holdings, Raises Price Target to $19 Morgan Stanley analyst Jeffrey Hung maintains enGene Holdings (NASDAQ:ENGN) with a Overweight and raises the price target from $18 to $19.